Literature DB >> 1611626

Photo-immunotargeting with haematoporphyrin conjugates activated by a low-power He-Ne laser.

T Berki1, P Németh.   

Abstract

A combined method has been developed for selective cytolysis in vitro as well as in vivo using a photosensitizer haematoporphyrin-protein conjugate as the targeting molecule and low-power He-Ne laser (632.8 nm) irradiation in order to activate the sensitizer to its excited, toxic triplet energy state. The specificity of the procedure was demonstrated in vitro by purging a mixed cell population from one component, and in vivo in an animal (nude mice) xenograft tumour model, where human cancer cells were destroyed by the immunotargeting method using monoclonal-antibody-haematoporphyrin (mAb-HP) conjugate (a-PNAr-I mAbs, which bind to the cell surface antigens of gastric cancer cells) and soft laser irradiation. The cell destruction was dependent on the doses of both mAb-HP and He-Ne laser light energy, and occurred only in target cell populations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1611626     DOI: 10.1007/bf01741058

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  29 in total

1.  The use of a derivative of hematoporhyrin in tumor detection.

Authors:  R L LIPSON; E J BALDES; A M OLSEN
Journal:  J Natl Cancer Inst       Date:  1961-01       Impact factor: 13.506

2.  Porphyrin photosensitization of proteins in cell membranes as studied by spin-labelling and by quantification of DTNB-reactive SH-groups.

Authors:  J Moan; A I Vistnes
Journal:  Photochem Photobiol       Date:  1986-07       Impact factor: 3.421

3.  Comparison of the efficacy of pulsed and continuous-wave red laser light in induction of photocytotoxicity by haematoporphyrin derivative.

Authors:  P A Cowled; J R Grace; I J Forbes
Journal:  Photochem Photobiol       Date:  1984-01       Impact factor: 3.421

4.  Continuous production of monoclonal mouse IgE antibodies with known allergenic specificity by a hybrid cell line.

Authors:  I Böttcher; G Hämmerling
Journal:  Nature       Date:  1978-10-26       Impact factor: 49.962

5.  Hematoporphyrin derivative for detection and treatment of cancer.

Authors:  T J Dougherty
Journal:  J Surg Oncol       Date:  1980       Impact factor: 3.454

6.  Ricin A-chain conjugated with monoclonal anti-L1210 antibody. In vitro and in vivo antitumor activity.

Authors:  K Kishida; Y Masuho; M Saito; T Hara; H Fuji
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Transplantation of cerebral actinomycosis simulating malignant brain tumor into nude mice. Report of a case.

Authors:  K Dávid; P Németh; Z Horváth; L Bartalos; A Horváth; G Hegedüs
Journal:  Zentralbl Neurochir       Date:  1985

8.  Guinea pig line 10 hepatocarcinoma model: characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain.

Authors:  M I Bernhard; K A Foon; T N Oeltmann; M E Key; K M Hwang; G C Clarke; W L Christensen; L C Hoyer; M G Hanna; R K Oldham
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

9.  Mechanism of the A/Ph.MC.S1 tumor graft rejection in syngeneic mice.

Authors:  J Zákány; T Jánossy; P Németh; G Chihara; J Fachet; G Petri
Journal:  Gan       Date:  1983-10

10.  Singlet oxygen generation of porphyrins, chlorins, and phthalocyanines.

Authors:  S Kimel; B J Tromberg; W G Roberts; M W Berns
Journal:  Photochem Photobiol       Date:  1989-08       Impact factor: 3.421

View more
  2 in total

1.  Adjuvant laser acupuncture in the treatment of whiplash injuries: a prospective, randomized placebo-controlled trial.

Authors:  Nicolas Aigner; Christian Fialka; Christian Radda; Vilmos Vecsei
Journal:  Wien Klin Wochenschr       Date:  2006-03       Impact factor: 1.704

Review 2.  Development of Novel Tetrapyrrole Structure Photosensitizers for Cancer Photodynamic Therapy.

Authors:  Natalia Plekhova; Olga Shevchenko; Oksana Korshunova; Aleksandra Stepanyugina; Ivan Tananaev; Vladimir Apanasevich
Journal:  Bioengineering (Basel)       Date:  2022-02-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.